Advertisement
UK markets close in 5 hours 51 minutes

  • FTSE 100

    8,078.38
    +33.57 (+0.42%)
     

  • FTSE 250

    19,781.57
    -18.15 (-0.09%)
     

  • AIM

    754.98
    +0.11 (+0.01%)
     

  • GBP/EUR

    1.1630
    +0.0002 (+0.01%)
     

  • GBP/USD

    1.2432
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    53,341.21
    +86.98 (+0.16%)
     

  • CMC Crypto 200

    1,433.64
    +9.54 (+0.67%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.89
    -0.47 (-0.56%)
     

  • GOLD FUTURES

    2,326.20
    -15.90 (-0.68%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,183.40
    +45.75 (+0.25%)
     

  • CAC 40

    8,117.75
    +11.97 (+0.15%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

Reuters
FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco

(Reuters) - Amgen Inc <AMGN.O> on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion (£10.3 billion)acquisition of Celgene Corp's psoriasis therapy Otezla.

Bristol-Myers Squibb Co <BMY.N>, which completed its buyout of Celgene on Wednesday, had agreed to divest the drug for the merger to go through.

Amgen now expects 2019 adjusted earnings per share between $14.50 and $14.70, up from its prior range of $14.20 to $14.45.

Full-year revenue is now expected between $23.1 billion and $23.3 billion, compared with the previous range of $22.8 billion to $23.0 billion.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)